Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma

References

• Fernandez de Larrea C, Kyle RA, Durie BG, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013;27(4):780–791.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Nair B, Qu P, et al. Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with total therapy protocols. Leukemia. 2012;26(11):2398–2405.
   PubMed Web of Science ®Google Scholar
• Mosca L, Musto P, Todoerti K, et al. Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. Am J Hematol. 2013;88(1):16–23.
   PubMed Web of Science ®Google Scholar
• Todoerti K, Agnelli L, Fabris S, et al. Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. Clin Cancer Res. 2013;19(12):3247–3258.
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck C, Barillé S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998;12(12):1977–1982.
   PubMed Web of Science ®Google Scholar
• Garcı́a-Sanz R, Orfão A, González M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93(3):1032–1037.
   PubMed Web of Science ®Google Scholar
• Pierre Noel RAK. Plasma cell leukemia: an evaluation of response to therapy. Am J Med. 1987;83:1062–1068.
   PubMed Web of Science ®Google Scholar
• Gundesen MT, Lund T, Moeller HEH, et al. Plasma cell leukemia: definition, presentation, and treatment. Curr Oncol Rep. 2019;21(1):8.
   PubMed Web of Science ®Google Scholar
• An G, Qin X, Acharya C, et al. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. Ann Hematol. 2015;94(2):257–264.
   PubMed Web of Science ®Google Scholar
• Ravi P, Kumar SK, Roeker L, et al. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo clinic study with comparison of outcomes to multiple myeloma. Blood Cancer J. 2018;8(12):116.
   PubMedGoogle Scholar
• Group TIMW. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–757.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2017.
   Google Scholar
• Jeong D, Lee DS, Kim N, et al. Prevalence of germline predisposition gene mutations in pediatric acute myeloid leukemia: genetic background of pediatric AML. Leuk Res. 2019;85:106210.
   PubMed Web of Science ®Google Scholar
• Hernández JM, Gutiérrez NC, Almeida J, et al. IL-4 improves the detection of cytogenetic abnormalities in multiple myeloma and increases the proportion of clonally abnormal metaphases. Br J Haematol. 1998;103(1):163–167.
   PubMed Web of Science ®Google Scholar
• Park JH, Kim M, Kong SY, et al. Monitoring of the clonal fraction by fluorescence in situ hybridization in myelodysplastic syndrome: comparison with International Working Group treatment response criteria. Arch Pathol Lab Med. 2016;140(6):560–569.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863–2869.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95(5):548–567.
   PubMed Web of Science ®Google Scholar
• Jean McGowan-Jordan AS, Schmid M, editors. ISCN: an international system for human cytogenomic nomenclature 2016. Basel (Switzerland): Karger.
   Google Scholar
• Jung KS, Hong K-W, Jo HY, et al. KRGDB: the large-scale variant database of 1722 Koreans based on whole genome sequencing. Database. 2020;2020:baz146.
   PubMedGoogle Scholar
• Lee N, Kim SM, Lee Y, et al. Prognostic value of integrated cytogenetic, somatic variation, and copy number variation analyses in Korean patients with newly diagnosed multiple myeloma. PLOS One. 2021;16(2):e0246322.
   PubMed Web of Science ®Google Scholar
• Cifola I, Lionetti M, Pinatel E, et al. Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. Oncotarget. 2015;6(19):17543–17558.
   PubMedGoogle Scholar
• Schinke C, Boyle EM, Ashby C, et al. Genomic analysis of primary plasma cell leukemia reveals complex structural alterations and high-risk mutational patterns. Blood Cancer J. 2020;10(6):70.
   PubMed Web of Science ®Google Scholar
• Neri A, Todoerti K, Lionetti M, et al. Primary plasma cell leukemia 2.0: advances in biology and clinical management. Expert Rev Hematol. 2016;9(11):1063–1073.
   PubMed Web of Science ®Google Scholar
• Kraj M, Kopec-Szlezak J, Poglod R, et al. Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia. Leuk Res. 2011;35(2):169–176.
   PubMed Web of Science ®Google Scholar
• Jung S-H, Lee J-J, Kim K, et al. The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). Oncotarget. 2017;8(45):79517–79526.
   PubMedGoogle Scholar
• Tiedemann RE, Gonzalez-Paz N, Kyle RA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia. 2008;22(5):1044–1052.
   PubMed Web of Science ®Google Scholar
• Chiecchio L, Dagrada GP, White HE, et al. Frequent upregulation of MYC in plasma cell leukemia. Genes Chromosomes Cancer. 2009;48(7):624–636.
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–421.
   PubMed Web of Science ®Google Scholar
• Alexandrov Ludmil B, Nik-Zainal S, Wedge David C, et al. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 2013;3(1):246–259.
   PubMed Web of Science ®Google Scholar